MEI Pharma Inc

Find Ratings Reports
MEIP : NASDAQ : Health Care
$2.67 -0.02 | -0.74%
Today's Range: 2.65 - 2.71
Avg. Daily Volume: 379000.0
09/20/17 - 3:43 PM ET

Financial Analysis


MEI PHARMA INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Even though it increased sales and net income significantly, the company was unable to grow at a faster pace than its industry competitors. MEI PHARMA INC is extremely liquid. Currently, the Quick Ratio is 11.01 which clearly shows the ability to cover any short-term cash needs. MEIP managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

During the same period, stockholders' equity ("net worth") has increased by 22.05% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY17 Q4 FY16
Net Sales ($mil)0.450.0
EBITDA ($mil)-4.4-5.81
EBIT ($mil)-4.44-5.82
Net Income ($mil)-4.34-5.77


Balance Sheet Q4 FY17 Q4 FY16
Cash & Equiv. ($mil)53.5745.92
Total Assets ($mil)55.747.16
Total Debt ($mil)0.00.0
Equity ($mil)50.8441.65


Profitability Q4 FY17 Q4 FY16
Gross Profit Margin-110.470.0
EBITDA Margin-978.840.0
Operating Margin-988.420.0
Sales Turnover0.420.0
Return on Assets4.79-44.23
Return on Equity5.25-50.08
Debt Q4 FY17 Q4 FY16
Current Ratio11.378.48
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q4 FY17 Q4 FY16
Shares outstanding (mil)36.7734.16
Div / share0.00.0
EPS-0.12-0.17
Book value / share1.381.22
Institutional Own % n/a n/a
Avg Daily Volume376769.0266294.0

Valuation


SELL. This stock's P/E ratio indicates a premium compared to an average of 39.88 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 24.88. To use another comparison, its price-to-book ratio of 1.91 indicates a discount versus the S&P 500 average of 3.10 and a significant discount versus the industry average of 12.14. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MEIP 44.00 Peers 39.88   MEIP 27.85 Peers 27.93

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

MEIP is trading at a premium to its peers.

 

Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MEIP is trading at a valuation on par to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MEIP NM Peers 25.67   MEIP NM Peers 0.50

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

MEIP's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MEIP's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MEIP 1.91 Peers 12.14   MEIP 109.83 Peers 10.47

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MEIP is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

MEIP is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MEIP 4.18 Peers 94.57   MEIP NA Peers 233.22

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MEIP is trading at a significant discount to its industry on this measurement.

 

Neutral. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.

The growth rate for MEIP is not available.

 

 

Latest Stock Upgrades/Downgrades